October 23, 2019

Boehringer Ingelheim completes US$76-million expansion of US vaccine plant

Boehringer Ingelheim has completed its US$76 million expansion of its vaccine manufacturing plant in Athens, Georgia, allowing it to double the facility's capacity, Veterinary Practice News reported last week.

"(This) announcement is representative of the growth and investment Boehringer Ingelheim is making around the US," says company president, Everett Hoekstra. "It also signals our commitment to a world in which no animal suffers from preventable disease."

Headquartered in Duluth, Ga., the company's US animal health business raised its manufacturing capacity at several sites in recent years, both in Georgia and in St. Joseph, Missouri, where the company has been operating for more than a century.

Boehringer Ingelheim employs about 440 people in Athens. The site produces more than 150 vaccines for poultry, pets and wildlife, which are sold in more than 80 countries.